Clinical trialPhase 1Not yet recruiting
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
An Exploratory Clinical Study of Peptide Nanovaccine (ONVAX-01) and Anti-PD-1 Antibody Combined With Chemotherapy for the Treatment of Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 20 June 2026
- Expected end
- 1 September 2029
- Enrollment
- 9 participants
- Sites
- 1
- Primary outcomes
- Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Sponsor
- Other
- Results posted
- No
- Last update
- 10 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer. The main questions it aims to answer are: 1. Is the combination of the peptide nanovaccine (ONVAX-01), an anti-PD-1 antibody, and chemotherapy safe and well-tolerated? 2. Does this combination treatment help shrink tumors or stop the progression of advanced pancreatic cancer? Participants will be asked to: 1. Receive doses of the peptide nanovaccine (ONVAX-01). 2. Receive intravenous infusions of an anti-PD-1 antibody and standard chemotherapy. 3. Undergo regular physical exams, blood tests, and imaging scans (such as CT or MRI) to monitor their health and the tumor's response to the treatment.